NDC 13913-004

Gralise

Gabapentin

Gralise is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Assertio Therapeutics, Inc.. The primary component is Gabapentin.

Product ID13913-004_15b124c8-345a-3a45-2c20-fbe258fb82b3
NDC13913-004
Product TypeHuman Prescription Drug
Proprietary NameGralise
Generic NameGabapentin
Dosage FormTablet, Film Coated
Route of AdministrationORAL
Marketing Start Date2011-01-28
Marketing CategoryNDA / NDA
Application NumberNDA022544
Labeler NameAssertio Therapeutics, Inc.
Substance NameGABAPENTIN
Active Ingredient Strength300 mg/1
Pharm ClassesAnti-epileptic Agent [EPC],Decreased Central Nervous System Disorganized Electrical Activity [PE]
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 13913-004-19

90 TABLET, FILM COATED in 1 BOTTLE (13913-004-19)
Marketing Start Date2011-01-28
Marketing End Date2023-09-30
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 13913-004-19 [13913000419]

Gralise TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA022544
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2011-01-28

NDC 13913-004-13 [13913000413]

Gralise TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA022544
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2011-01-28
Marketing End Date2015-12-31

NDC 13913-004-91 [13913000491]

Gralise TABLET, FILM COATED
Marketing CategoryNDA
Application NumberNDA022544
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2017-10-01

Drug Details

Active Ingredients

IngredientStrength
GABAPENTIN300 mg/1

OpenFDA Data

SPL SET ID:7d12b4e9-ed44-43c0-9e46-f6c195300f03
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1115015
  • 1115016
  • 1115012
  • 1115013
  • 1806382
  • 1806380
    • UPC Code
  • 0313913004196
  • 0313913004912
  • 0313913005193

    • Pharmacological Class

    • Anti-epileptic Agent [EPC]
    • Decreased Central Nervous System Disorganized Electrical Activity [PE]

    Medicade Reported Pricing

    13913000419 GRALISE ER 300 MG TABLET

    Pricing Unit: EA | Drug Type:

    13913000413 GRALISE ER 300 MG TABLET

    Pricing Unit: EA | Drug Type:

    NDC Crossover Matching brand name "Gralise" or generic name "Gabapentin"

    NDCBrand NameGeneric Name
    13913-004GraliseGralise
    13913-005GraliseGralise
    50436-1262GraliseGralise
    52427-803GraliseGralise
    52427-806GraliseGralise
    52427-815GraliseGralise
    0093-4443GabapentinGabapentin
    0093-4444GabapentinGabapentin
    0143-3991GabapentinGabapentin
    0143-3993GabapentinGabapentin
    0143-3994GabapentinGabapentin
    0143-9992GabapentinGabapentin
    0143-9993GabapentinGabapentin
    0143-9994GabapentinGabapentin
    0071-0401Neurontingabapentin
    0071-0513Neurontingabapentin
    0071-0803Neurontingabapentin
    0071-0805Neurontingabapentin
    0071-0806Neurontingabapentin
    0071-2012Neurontingabapentin

    Trademark Results [Gralise]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    GRALISE
    GRALISE
    88511419 not registered Live/Pending
    Assertio Therapeutics, Inc.
    2019-07-12
    GRALISE
    GRALISE
    86982952 5312458 Live/Registered
    ASSERTIO THERAPEUTICS, INC.
    2016-01-14
    GRALISE
    GRALISE
    86875330 not registered Dead/Abandoned
    ASSERTIO THERAPEUTICS, INC.
    2016-01-14
    GRALISE
    GRALISE
    77934261 4132334 Live/Registered
    ASSERTIO THERAPEUTICS, INC.
    2010-02-12
    © 2025 FDA.report
    This site is not affiliated with or endorsed by the FDA.